Myelodysplastic Syndrome Clinical Trial
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
This is a single arm pilot study for patients using α/β T cell-depleted peripheral Stem Cell Transplantation (PSCT) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and graft versus host disease (GVHD), and one year leukemia free survival.
Acute myeloid leukemia, primary or secondary Disease status: remission or <10% bone marrow blasts
Acute lymphoblastic leukemia Disease status: in hematologic remission
Chronic myelogenous leukemia Disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase.
Mixed lineage or biphenotypic acute leukemia
Lymphoblastic lymphoma Disease status: remission
Burkitt's lymphoma/leukemia: Disease status- in remission
Acceptable organ status clearance
No active untreated infection. Patients with possible fungal infections must have had at least 2 weeks of appropriate anti-fungal antibiotics and be asymptomatic
Signed informed consent.
Negative pregnancy test for females of childbearing potential.
Patients who do not meet disease, organ or infectious criteria.
No suitable donor
Received previous allogeneic transplant
Donor must be either unrelated, mismatched up to one antigen/one antigen and one allele or a related, HLA match other than a sibling.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19103, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.